rheumatology

News in brief: Tofacitinib looks promising in AS; Call to curb spinal procedure for LBP; Rituximab improves neuro-psychiatric lupus

Promise for JAK inhibition in AS The JAK inhibitor tofacitinib keeps on giving – now demonstrating significantly greater efficacy versus placebo in adults with active ankylosing spondylitis. A phase 3 RCT of 269 patients found the ASAS20 response rate at week 16 with 5mg tofacitinib was 56.4% versus 29.4% in controls (p<0.0001) and ASAS40 response ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic